ArticleBlood advances2025

Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies.

Tusneem Janoudi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.